The combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) elicited promising progression-free survival (PFS) outcomes in patients with uveal melanoma who were both HLA-A*02:01–negative and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback